US 12,435,113 B2
Prefusion PIV F immunogens and their use
Baoshan Zhang, Bethesda, MD (US); Guillaume Stewart-Jones, Cambridge, MA (US); Tongqing Zhou, Boyds, MD (US); John Mascola, Rockville, MD (US); Kai Xu, Rockville, MD (US); Yongping Yang, Potomac, MD (US); Paul Thomas, Washington, DC (US); Gwo-Yu Chuang, Rockville, MD (US); Li Ou, Potomac, MD (US); Peter Kwong, Washington, DC (US); Yaroslav Tsybovsky, Brunswick, MD (US); Wing-Pui Kong, Germantown, MD (US); Aliaksandr Druz, Germantown, MD (US); Davide Corti, Bellinzona (CH); and Antonio Lanzavecchia, Bellinzona (CH)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and Institute for Research in Biomedicine, Bellinzona (CH)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and Institute for Research in Biomedicine, Bellinzona (CH)
Filed on Dec. 12, 2023, as Appl. No. 18/537,448.
Application 18/537,448 is a division of application No. 17/378,587, filed on Jul. 16, 2021, granted, now 11,845,778.
Application 17/378,587 is a division of application No. 16/344,772, granted, now 11,078,239, issued on Aug. 31, 2021, previously published as PCT/US2017/058322, filed on Oct. 25, 2017.
Claims priority of provisional application 62/412,699, filed on Oct. 25, 2016.
Prior Publication US 2024/0101609 A1, Mar. 28, 2024
Int. Cl. C07H 21/02 (2006.01); A61K 39/155 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/155 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); C07K 2319/50 (2013.01); C12N 2760/18634 (2013.01); C12N 2760/18734 (2013.01)] 27 Claims
OG exemplary drawing
 
1. An isolated nucleic acid molecule, encoding a recombinant human parainfluenza virus (hPIV)3 F ectodomain comprising amino acid substitutions that stabilize a trimer of the recombinant hPIV3 ectodomain in a prefusion conformation, wherein the amino acid substitutions comprise:
463V and/or 474Y cavity filling substitutions; and/or
one or more of the following sets of substitutions to form a disulfide bond:
162C and 168C;
213C and 230C;
170C and 242C;
216C and 221C;
85C and 222C; and
172C and 238C, and
wherein amino acid substitution numbering is according to a reference hPIV3 F sequence set forth as SEQ ID NO: 9 .